期刊
EXPERT OPINION ON DRUG DISCOVERY
卷 13, 期 12, 页码 1141-1151出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17460441.2018.1543267
关键词
Alzheimer's disease; A beta inhibition; ChEs inhibitors; chromones; MTDLs
Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disorder responsible for the great majority of age-related dementias affecting daily life through memory loss and cognitive impairment. From a molecular point of view, the most common neuropathological characteristics found in AD patients are abnormal protein deposits, particularly senile plaques (SP) and neurofibrillary tangles (NFT). Furthermore, the currently available pharmacological treatment only provides short-term improvements and is focused on the use of cholinesterase (ChEs) inhibitors or memantine, an approved medicine that is a glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker. Areas covered: This review is focused on the relevance of chromones for future AD treatment. Structure-activity relationship (SAR) studies which look at the inhibition of amyloid-beta (A beta) plaque formation and aggregation and the inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase are also discussed. Expert opinion: SAR studies are a useful strategy for the elucidation of structural features that improve compound-specific AD-related activities. The development of multi-target-directed ligands (MTDLs) represents an exciting challenge for organic chemists. As such, recently developed chromone-type compounds have a potential use as MTDLs for the treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据